Evotec AG and Roche AG today announced that they have entered into an exclusive world-wide license agreement for the development and commercialisation of Evotec’s MAO-B inhibitor to treat Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-roche-agree-to-develop-compound-that-could-slow-the-progression-of-alzheimers-disease-5597
Ad hoc:Evotec acquires compound management business from Galapagos
Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hocevotec-acquires-compound-management-business-from-galapagos-5595
Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-5593